A Phase 1 Study of the Relative Bioavailability of Two PRN1008 Tablet Formulations, Effect of PRN1008 on Midazolam Pharmacokinetics, and Impact of Famotidine on PRN1008 Pharmacokinetics in Healthy Subjects
Latest Information Update: 16 Jul 2019
Price :
$35 *
At a glance
- Drugs Rilzabrutinib (Primary) ; Famotidine; Midazolam
- Indications Autoimmune disorders; Idiopathic thrombocytopenic purpura; Pemphigus vulgaris
- Focus Pharmacokinetics
- Sponsors Principia Biopharma
- 30 Apr 2018 Status changed from not yet recruiting to completed.
- 19 Feb 2018 New trial record